Statin-Induced Musculoskeletal Problems: Disconcerting Reports and Data by Manolis, Antonis S
Statin-Induced Musculoskeletal Problems: 
Disconcerting Reports and Data*
Antonis S. Manolis, MD
A b s t r A c t
Statins are being increasingly employed for both primary and secondary prevention 
of cardiovascular disease due to their hypocholesterolemic action and a variety of fa-
vorable pleiotropic effects. However, this ubiquitous growing use of statins has led to a 
higher incidence of intolerance to these hypolipidemic agents. This is particularly due 
to development of musculoskeletal problems, which have been apparently underesti-
mated in controlled trials, but are increasingly reported in real-world clinical practice. 
A brief review of these disconcerting reports and data is herein discussed.
Statins are molecules of fungal origin, which inhibit the hydroxymethylglutaryl-CoA 
reductase enzyme, a key step in the sterol biosysnthesis, rendering them powerful cho-
lesterol lowering medications contributing to significant prevention of cardiovascular 
disease.1 Statins are characterized by differences in bioavailability, lipo/hydrophilicity, 
cytochrome P-450 mediated metabolism and cellular transport mechanisms, differences 
that are reflected in their relative capacity in low-density lipoprotein (LDL)-cholesterol 
lowering and possibly in parenchymal or muscular toxicities.2 Statin intolerance com-
prises, among others, musculoskeletal problems, such as statin-induced muscle and 
tendon disorders which are the most common cause of statin discontinuation.3-10
M u s c u l o s k e l e t A l  P r o b l e M s
Statin therapy has long been associated with musculoskeletal problems in approxi-
mately 10%-25% of patients treated in real-world clinical practice, but such problems 
have rarely been reported in controlled clinical trials,3,4 and their incidence has thus far 
been underestimated.5 Studies have concentrated on creatine kinase (CK) elevations to 
identify myopathy. However, many patients can have normal serum CK levels despite 
myalgia and persistent weakness and muscle biopsy - proven myopathy. Discontinuation 
of statin and rechalllenge may be required to prove that it is statin-related. Several risk 
factors may predispose patients to statin-related musculoskeletal problems, including 
advanced age, family history of myopathy, statin dose, and interacting medications 
(e.g., azole antifungals, cimetidine, fibrates, macrolide antibiotics, protease inhibitors 
and cyclosporine) (Table 1).5,6,8
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Musculoskeletal conditions, arthropathies, injuries, and 
pain appear to be more common among statin users than 
among similar nonusers. In a recent retrospective cohort 
study (N= 46,249; 13,626 statin users and 32,623 nonusers) 
with propensity score matching (n=6967 statin users; n= 
6967 nonusers),7 the authors investigated whether statin use 
was associated with musculoskeletal conditions, including 
arthropathy and injury, in a military health care system. Statin-
associated musculoskeletal adverse effects include a wide array 
of clinical presentations, including myalgias, muscle weakness, 
muscle cramps, rhabdomyolysis, autoimmune muscle disease, 
and tendinous diseases. Among matched pairs, statin users 
had a higher odds ratio (OR) for all musculoskeletal diseases 
(OR, 1.19), injury-related diseases (dislocation, sprain, strain) 
(1.13), and drug-associated musculoskeletal pain (1.09); the 
OR for arthropathies and related diseases was 1.07 (P = 0.07). 
Secondary and sensitivity analyses revealed higher adjusted 
odds ratios for statin users in all outcome groups. The authors 
concluded that musculoskeletal conditions, arthropathies, 
injuries, and pain are more common among statin users than 
among similar nonusers.
A recent large cohort study reporting on discontinuation 
of statins in routine care settings indicated that statins were 
discontinued at least temporarily for 57,292 out of 107,835 
patients.9 Statin-related events were documented for 18,778 
(17.4%) patients, - a substantially higher rate than the 5-10% 
rate usually described in randomized placebo-controlled clini-
cal trials. Similar to both clinical trials and observational stud-
ies, musculo-skeletal symptoms predominated - accounting for 
40% of statin-related events. However, overt rhabdomyolysis 
was found in only 0.006% of the study patients, also consistent 
with previous reports that statin-induced severe myopathy is a 
rare event. In this study, the majority (>90%) of patients who 
were rechallenged with a statin after a statin-related event, 
were finally able to tolerate one. The authors concluded that 
statin-related events are commonly reported and often lead 
to the discontinuation of statins; nearly 1 in 5 patients in this 
cohort stopped all statins for at least 12 months. However, most 
patients who are rechallenged can tolerate statins long-term. 
This suggests that many of the statin-related events may have 
other etiologies, are tolerable or may be specific to individual 
statins rather than the entire drug class.
M y o P A t h I e s
The above and other recent papers on statin-induced 
myopathy have lately spawned an intense discussion and con-
troversy regarding the results of randomized controlled trials 
reporting a much lower incidence of such adverse effects.7,9,11-14 
A recent review and meta-analysis of observational studies has 
confirmed the increased incidence of statin-related myopathy 
with an odds ratio of 2.63,15 further fueling the heated discus-
sion emanating from the recent guidelines recommending 
an expansion of the population base to receive statins. The 
authors of that review indicate that their analysis giving higher 
estimates than randomized controlled trials for myopathy 
may reflect differences in the diagnostic criteria used and the 
populations studied. They emphasize that myopathy is more 
likely to occur with higher doses of statins and randomized 
controlled trials have excluded situations that raise statin blood 
levels, including advanced age, frailty, deterioration of renal 
function and the presence of interacting drugs.
The spectrum of statin-related myopathies ranges from 
common, albeit clinically benign, myalgia without CK elevation 
to typical myositis with CK elevation to rare but life-threat-
ening rhabdomyolysis. It is estimated by observational studies 
that 10-15% of statin users develop statin-related muscle side 
effects. Fortunately, the more severe form of rhabdomyolysis 
remains rare.3-9
The mechanisms of statin-related myopathies have not 
been clearly elucidated. However, strong evidence has emerged 
from observational and clinical studies that skeletal muscle 
toxicity is a dose-dependent feature associated with all statins, 
with some (lipophilic) statins being more toxic than others 
(hydrophilic statins), primarily related to the reduced avail-
tAble 1. Risk Factors for Developing Statin-Related 
Musculoskeletal Problems
Age >75-80 years old drugs
Female gender Fibrates
low bMI, frail Cyclosporine
history (or Fh) of muscle  
symptoms/disease/↑ck
Protease inhibitors
history (or Fh) of statin  
intolerance
Antibiotics: Macrolides/ 
Daptomycin/Antifungals (Azole)/ 
Rifampin/Fusidic acid
renal / liver disease Ranolazine
diabetes Amiodarone/Dronedarone
Vitamin d deficiency Verapamil/Diltiazem
hypothyroidism Cocaine
high-dose statin Danazol
type of statin Warfarin
Physical exercise Cimetidine
Major surgery Nefazodone
Genetic polymorphisms Colchicine
Grapefruit juice Nicotinic acid
Alcohol Dasatinib
bMI = body mass index; CK = creatine kinase; FH = family history
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ability of metabolites produced by the mevalonate pathway 
rather than intracellular cholesterol lowering per se which 
include alteration in isoprenoids synthesis.16 In general, there 
is a complex interplay between drug–environment and drug–
drug interaction in the context of different genetic settings 
contributing to statin-induced skeletal muscle toxicity. Of note, 
an important metabolite derived from cholesterol is vitamin 
D, produced when 7-dehydrocholesterol is converted by ul-
traviolet b light to active vitamin D3 in the skin. Importantly, 
vitamin D deficiency can cause muscle weakness, generalized 
muscle pain, and levels of vitamin D <30 nmol/L are associ-
ated with decreased muscle strength. Indeed, a cross-sectional 
study showed that low levels of vitamin D were associated with 
increased statin-induced skeletal muscle complaints17 suggest-
ing a reversible interaction between vitamin D deficiency and 
statins on skeletal muscle. However, the role of vitamin D 
on induction or protection from muscle toxicity during statin 
therapy remains unclear.
Options for managing statin myopathies include lower 
dose of statin, statin switching, particularly to fluvastatin or 
low-dose rosuvastatin; nondaily dosing regimens;18,19 nonstatin 
alternatives, such as ezetimibe and bile acid-binding resins 
(colesevelam); and coenzyme Q10 supplementation. How-
ever, the evidence supporting such strategies remains scanty. 
Re-initiation of statins in a patient who has exhibited statin-
related musculoskeletal problems should be individualized 
and caution should be exercised.20,21 If the diagnosis of statin-
induced myopathy was correct and there were no modifiable 
risk factors, the likelihood is high that the problem will recur 
upon rechallenge with same statin at the same dose. A modi-
fied approach by switching to another statin and using a low 
dose may reduce the risk of recurrence.
Statin-related myopathies will probably become more 
prevalent in the future with greater numbers of persons be-
ing placed on statin therapy, as recommended by the recent 
American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines,1,8 despite the controversy they 
have invoked, and thus there is need for further research to 
better identify patients at risk for statin myopathy and to 
evaluate management strategies for statin-related myopathy.
t e N d I N o P A t h I e s
In addition to muscle toxicity, statins have also been 
implicated in drug-induced tendon toxicity, which is rare but 
often underestimated.7,22 Statins are among the four main 
drug classes which have been incriminated in tendinopathies,23 
with quinolones and long-term glucocorticoids being the most 
widely known, but statins and aromatase inhibitors can also 
induce tendon damage. The pathophysiological mechanisms 
underlying drug-induced tendinopathies remain unknown. 
Identified risk factors may include age >60 years, pre-existing 
tendinopathy, and drug combinations potentiating these toxic 
effects. Mean time to symptom onset varies among the drug 
classes and reaches several months for statins. The most 
frequent sites of involvement are the lower limb tendons, 
most commonly the Achilles tendon. The most dramatic 
clinical manifestation of tendininous disorders is tendon rup-
ture.10,24,25 Tendon rupture usually occurs in injured tendons. 
Physiological repair of an injured tendon requires degradation 
and remodeling of the extracellular matrix through matrix 
metalloproteinases (MMPs). The authors of a statin-related 
spontaneous biceps tendon rupture have put forth the hy-
pothesis that statins may increase the risk of tendon rupture 
by inhibiting MMP activity.24
French investigators have analyzed 96 reports of tendon 
disorders attributed to statins.10 Patients had tendinitis (66%) 
and tendon rupture (34%). The Achilles tendon was most 
often affected. This adverse effect mainly occurred during 
the first year of treatment and appeared to be more frequent 
in patients with diabetes, hyperuricemia or a history of ten-
don disorders, and in persons engaging in strenuous sports. 
Reinitiation of statin in a few cases resulted in recurrence of 
tendinopathy in all cases. In practice, tendinopathy appears 
to be a rare adverse effect of statins, but patients should be 
closely monitored during the first year of treatment, especially 
when they have associated risk factors.
A u t o I M M u N e  N e c r o t I c  M y o s I t I s
Persistent weakness after statin withdrawal has also been 
reported, attributed to a severe form of autoimmune necrotic 
myositis triggered by statins; successful treatment has been ap-
plied with use of intravenous immunoglobulins, combined with 
steroids and metothrexate.26 Detection of serum antibodies 
to the target enzyme of statins (3-hydroxy-3-methylglutaryl-
coenzyme A reductase) has been reported in cases of inflam-
matory and necrotizing myopathies.27,28 Even myasthenia gravis 
has been associated with intake of statins. 29
s t A t I N  M u s c l e  s A F e t y  t A s k  F o r c e
Recently, a Statin Muscle Safety Task Force, the National 
Lipid Association’s Muscle Safety Expert Panel, was convened 
and charged with the duty of examining the definitions for 
statin-related musculoskeletal problems, development of 
a clinical index to assess myalgia, and the use of diagnostic 
neuromuscular studies to investigate muscle adverse events.30 
The Panel developed an algorithm for the evaluation and treat-
ment of patients who may be intolerant to statins as the result 
of adverse muscle events. The Panel has attempted to answer 
this year’s questions. The answer was affirmative to the first 
question of whether statin-associated myalgia could be reliably 
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differentiated from myalgia associated with a placebo, based 
on the results of the STOMP trial.31 For this purpose, the sug-
gested standard definition of statin-related myalgia includes:
 - new-onset or increased symptoms of myalgia (muscle 
aches, stiffness, cramping, soreness, and tenderness) that 
are unassociated with recent exercise;
 - symptoms that persist for at least 2 weeks;
 - symptoms that resolve within 2 weeks of stopping the 
study drug; and
 - symptoms that recur within 4 weeks of restarting the 
medication.
The Panel admitted that there have been no validated 
scales to diagnose statin-associated myalgia. Nevertheless, 
they propose a quantitative myalgia score that is largely based 
on the findings from the STOMP trial.31 This statin myalgia 
clinical index score rates the symptoms as probable, possible, 
or unlikely related to statin. Statin-associated muscle pain 
usually affects the lower limbs, as reported in the PRIMO 
study,3 and is likely to occur within the first month of therapy.
The Panel indicated that statins are less tolerated in 
physically active individuals, as the statin-associated muscle 
complaints are proportional to the acute and chronic physical 
activity.30 The data suggest that statin therapy may produce a 
greater incidence of muscle-related side effects in chronically 
physically active individuals and may also exacerbate skeletal 
muscle damage and CK release during acute exercise. The 
Panel also provided diagnostic criteria for statin-induced 
myopathy, which include proximal weakness detected on physi-
cal examination and standardized muscle testing and finally 
confirmed by electromyography plus/minus muscle biopsy. For 
the timing of muscle biopsy, the Panel recommended to start 
with an electromyogram, and to proceed to biopsy in those 
individuals with fibrillations and/or positive sharp waves in 
the affected muscles to assist in correctly diagnosing the type 
of muscle disorder that is responsible for the CK elevation, 
after a thorough neurological examination has excluded certain 
neuropathies and radiculopathies.
The Panel also agreed that according with retrospective 
data derived from registries, most (~90%) patients who are 
intolerant to one statin because of myalgia can generally toler-
ate a different statin.30 Although some propose a statin that 
is independent of cytochrome P450 3A4 metabolism such as 
pravastatin, rosuvastatin, fluvastatin, or pitavastatin, there have 
been no randomized studies confirming this recommendation. 
Some have suggested that lipophilic statins (simvastatin/lovas-
tatin) are more likely to produce muscular effects as opposed 
to the more hydrophilic statins (pravastatin, rosuvastatin, 
and fluvastatin), but again this needs to be put to test by ap-
propriately designed studies. Others have related the muscle 
toxicity to specific drug potency, with relative adverse event 
risks being higher with higher potency statins.32
For statin-intolerant patients, the Panel recommends 
alternate-day or non-daily dosing with statins of long half-
life (rosuvastatin and atorvastatin),19 although these dosing 
regimens have not been studied in terms of their effective-
ness in reducing cardiovascular events.18,30 Finally, when all 
else has failed, nonstatin LDL-cholesterol-lowering thera-
pies (ezetimibe, colesevelam) may be employed or added to 
low-dose statin therapy. Supplemental use of vitamin D or 
coenzyme Q10 has also been suggested but remains to be 
proven effective.
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